Peter J. Grua

Board Director

Director

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 1 buy · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€92k

▼ Sales (0 ops.)

—

Latest filing published 08 Jun 2026 for Evolent Health, Inc.. Read the official filing

Filing timeline

BuySale

Peter J. Grua

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

100%

T+90 mean return

+18.9%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Peter J. Grua: trading record in brief

This profile gathers the share dealings of Peter J. Grua in Evolent Health, Inc., where the filings describe the role as board member. The record holds 7 filings, for trades running from 10 June 2021 to 4 June 2026.

Purchases make up the whole of the open-market record (1 purchase, €92k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 6 share grants.

The record was last updated on 8 June 2026 with a share grant in Evolent Health, Inc. The clock since the last published purchase (10 March 2025) now reads 587 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.